## ARWR: Arrowhead Pharmaceuticals, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 1.5% below STRENGTH zone (3.0-6.0%); PEG unavailable fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($62.66)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 7
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Exchange Traded Concepts LLC Sells 15,265 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR**
- Source: MarketBeat | 20251228T090948 | Somewhat-Bullish | Relevance: 100%
- Exchange Traded Concepts LLC reduced its stake in Arrowhead Pharmaceuticals (NASDAQ:ARWR) by 33.0% in the third quarter, selling 15,265 shares. Institutional investors and hedge funds have shown mixed activity, with several increasing their positions in the biotechnology company. Analysts maintain a "Moderate Buy" consensus rating with an average price target of $61.89, while company insiders have been significant sellers.

**2. Assessing Arrowhead Pharmaceuticals (ARWR) Valuation After FDA Breakthrough Status for Plozasiran and Redemplo Launch**
- Source: Simply Wall Street | 20251225T050956 | Somewhat-Bullish | Relevance: 100%
- Arrowhead Pharmaceuticals (ARWR) recently received FDA Breakthrough Therapy designation for plozasiran and launched Redemplo, significantly boosting its stock. Despite a recent surge in share price, the company's valuation is deemed overvalued by Simply Wall St, with a narrative fair value of $64.08 against its current trading price of $70.11. The article suggests investors consider potential risks like disappointing Phase 3 data for plozasiran or slow Redemplo uptake.

**3. Texas Permanent School Fund Corp Buys Shares of 19,104 Arrowhead Pharmaceuticals, Inc. $ARWR**
- Source: MarketBeat | 20251227T100914 | Somewhat-Bullish | Relevance: 100%
- Texas Permanent School Fund Corp recently acquired 19,104 shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR), valued at approximately $302,000, marking a new position for the institutional investor. This purchase contributes to a total institutional ownership of about 62.61% for the company, despite recent insider selling. Analysts maintain a "Moderate Buy" rating for ARWR, with an average price target of $61.89, and some firms raising their targets significantly.

**4. Voya Investment Management LLC Has $4.74 Million Stock Position in Arrowhead Pharmaceuticals, Inc. $ARWR**
- Source: MarketBeat | 20251226T130922 | Somewhat-Bullish | Relevance: 100%
- Voya Investment Management LLC significantly increased its stake in Arrowhead Pharmaceuticals (NASDAQ:ARWR) by 158.2%, now owning 137,516 shares valued at $4.74 million. Institutional investors collectively hold 62.61% of the company, while several analysts have raised their price targets, indicating a "Moderate Buy" consensus. However, company insiders have recently been net sellers, offloading shares worth $23.67 million.

**5. Arrowhead Pharma director Vakiener sells $679k in stock**
- Source: Investing.com | 20251224T160922 | Neutral | Relevance: 100%
- Victoria Vakiener, a director at Arrowhead Pharmaceuticals (NASDAQ:ARWR), sold 9,940 shares of common stock totaling $679,491 on December 19, 2025, through a pre-arranged 10b5-1 trading plan. The sales occurred across three transactions with prices ranging from $66.63 to $68.39, just below the stock's 52-week high, leaving Vakiener with 35,723 directly owned shares. This comes amidst other positive company news, including the launch of a new drug, Redemplo, and several analyst price target increases.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 6, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-17 | Piper Sandler | $100 | $70 | +43% |
| 2025-12-11 | RBC Capital | $80 | $52 | +54% |
| 2025-12-09 | B of A Securiti | $81 | $62 | +31% |
| 2025-12-02 | HC Wainwright & | $85 | $80 | +6% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-17 | Piper Sandler | main | Overweight |
| 2025-12-11 | RBC Capital | main | Outperform |
| 2025-12-09 | B of A Securiti | main | Buy |
| 2025-12-02 | HC Wainwright & | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 8 ($0.00M) |
| Sells | 5 ($3.67M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 54.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 1 |

**Top Holders:**
- Blackrock Inc.: 14.9% (+4.1%)
- Vanguard Group Inc: 11.8% (+3.3%)
- Avoro Capital Adviso: 8.0% (+2.8%)
- State Street Corpora: 4.7% (+0.4%)
- FMR, LLC: 4.2% (+11.4%)

### Key Risks

1. Insider selling cluster: $3.7M in recent transactions.
2. Elevated short interest (9.8%): bears positioning against stock.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Analyst target momentum: 6 raises (avg +31%) could attract flows.
- Momentum building: MRS_10 improving +1.3% over 5 days suggests accumulation.

### Fundamentals

Balance sheet: strong liquidity (4.9x). Revenue declining -31% YoY, concerning. Analyst sentiment positive (6 raises, avg +31%). Insider selling cluster ($3.7M in 90 days), potential headwind. Institutional flow bullish (8 buying vs 1 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.7B |
| Beta | 1.29 |
| 52W Range | $9.57 - $72.36 |
| Short Interest | 9.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -1.32 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_10 strengthening from 0.1% to 1.5% (+1.3% in 5 days), confirming momentum buildup. Below STRENGTH zone by 1.5pp (needs >3.0% for momentum thesis). MRS_5 at 0.6% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-0.53), momentum weakening. OFD pattern: +DLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 1.46% (CS: 92) | Neutral |
| RSI_14 | 70.0 | Neutral |
| MACD Histogram | -0.53 | Bearish |
| vs SMA20 | 1.066x | Above |
| vs SMA50 | 1.384x | Above |
| vs SMA200 | 2.588x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $70.16
- **Stop Loss:** $62.66 (10.7% risk)
- **Target:** $77.66 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 176
- **Position Value:** $12,348.16
- **Portfolio %:** 12.35%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with selective risk appetite amid holiday trading. VIX at extreme lows (13.6) signals complacency while positive yield curve (+59bps) and stable economic data support continuation. Focus on quality names with AI/infrastructure exposure while monitoring January volatility reset.*

### Earnings

**Next:** 2026-02-09 (Est: $-0.10)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-0.16 | $-0.18 | -14.4% |
| 2025Q2 | $-1.10 | $-1.26 | -14.4% |
| 2025Q1 | $-0.46 | $2.75 | +695.0% |
| 2024Q4 | $-0.72 | $-1.39 | -92.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*